Luvox CR

See also: Generic Luvox

Luvox CR is a brand name of fluvoxamine, approved by the FDA in the following formulation(s):

LUVOX CR (fluvoxamine maleate - capsule, extended release; oral)

• 
  Manufacturer: JAZZ
  
  Approval date: February 28, 2008
  
  Strength(s): 100MG, 150MG ^[RLD]

Has a generic version of Luvox CR been approved?

No. There is currently no therapeutically equivalent version of Luvox CR available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Luvox CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
  Patent 7,465,462
  Issued: December 16, 2008
  Inventor(s): Jeary; Theresa Ann & Morrissey; Catherine Ann & Stark; Paul
  Assignee(s): Elan Pharma International Limited
  A multiparticulate controlled release selective serotonin reuptate inhibitor (SSRI) formulation for oral administration is provided. The formulation includes particles of an SSRI or a pharmaceutically acceptable salt thereof, which are coated with a rate-controlling polymer that allows controlled release of the SSRI over a period of not less than about 12 hours after oral administration. The rate controlling polymer includes a film-forming water-insoluble polymer, or a mixture of a film-forming water-insoluble polymer and a film-forming water-soluble polymer.
  
  Patent expiration dates:
  
  
  • May 10, 2020
    
    ✓ 
    Patent use: TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • February 28, 2011 - NEW DOSAGE FORM
  
  

See also...

• Luvox CR Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Luvox CR Consumer Information (Cerner Multum)
• Luvox CR Advanced Consumer Information (Micromedex)
• Fluvoxamine Consumer Information (Wolters Kluwer)
• Fluvoxamine Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Fluvoxamine Consumer Information (Cerner Multum)
• Fluvoxamine Advanced Consumer Information (Micromedex)
• Fluvoxamine Maleate AHFS DI Monographs (ASHP)